• Corpus ID: 34570861

Effects of Valproate, Phenobarbital, and Carbamazepine on Sex Steroid Setup in Women with Epilepsy

  title={Effects of Valproate, Phenobarbital, and Carbamazepine on Sex Steroid Setup in Women with Epilepsy},
  author={Giovanni Murialdo and Carlo Andrea Galimberti and Maria Vittoria Gianelli and Alessandro Rollero and Alessandro Polleri and Francesco Copello and Flavia Magri and Ettore Ferrari and Patrizia Sampaolo and Raffaele Manni and Amelia Tartara},
  journal={Clinical Neuropharmacology},
Serum levels of sex-hormones, sex-hormone binding globulin, gonadotropin, and prolactin were evaluated during the follicular and the luteal phases in 65 women with epilepsy and in 20 healthy controls. Twenty-one patients were treated with sodium valproate (VPA), 21 with phenobarbital (PB), and 23 with carbamazepine (CBZ). VPA does not stimulate liver microsome enzymes, whereas PB and CBZ do. Patients on VPA therapy showed higher body weight and body mass index, but no significant differences in… 
The steroid metabolome in lamotrigine-treated women with epilepsy
Antiepileptic drugs, sex hormones, and PCOS
The use of the liver enzyme–inducing AEDs—such as phenobarbital, phenytoin, and carbamazepine—can increase serum sex hormone–binding globulin concentrations, leading to diminished bioactivity of testosterone (T) and estradiol.
Valproate potentiates androgen biosynthesis in human ovarian theca cells.
The first biochemical evidence is provided to support a role for VPA in the genesis of polycystic ovary syndrome-like symptoms, and establish a direct link between VPA treatment and increased ovarian androgen biosynthesis.
Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy
In women, use of valproic acid appears to be associated with a frequent occurrence of reproductive endocrine disorders characterised by polycystic changes in the ovaries, high serum testosterone concentrations (hyperandrogenism) and menstrual disorders, and from a practical point of view, the length of the menstrual cycles and body weight should be monitored in women with epilepsy after commencement of treatment with valProic acid.
Polycystic ovaries, obesity and insulin resistance in women with epilepsy
The frequency of PCOs in 27 % of epileptic women seems to be similar to that in the general population with a frequency of 20–30 %, which indicates that VPA increases glucose stimulated pancreatic insulin secretion, which might be followed by an increase in body weight.
Long-Term Effects of Valproic Acid on Reproductive Endocrine Functions in Turkish Women with Epilepsy
No statistically significant dose or duration-related rise of risk for patients who developed PCOS and menstrual irregularities and those who were not on long-term VPA therapy support the hypothesis of early occurring VPA-associated metabolic and endocrine changes.
The Anti-Epileptic Drug Valproic Acid (VPA) Inhibits Steroidogenesis in Bovine Theca and Granulosa Cells In Vitro
Findings refute the hypothesis that VPA has a direct stimulatory action on TC androgen output and inhibit both LH-dependent androgen production and FSH/IGF-dependent estradiol production in this in vitro bovine model.
Reproductive Dysfunction in Women With Epilepsy: Antiepileptic Drug Effects on Sex-Steroid Hormones
With new AEDs available that do not alter cytochrome P450 enzymes, physician selection of therapy should consider not only seizure control, but also potential effects on reproductive physiology, as women with epilepsy are at risk for reproductive health dysfunction.
Epilepsy, sex hormones and antiepileptic drugs in female patients
The aim of the present review is to critically evaluate the recently published data concerning the interactions between sex hormones, epilepsy and AEDs.